BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

607 related articles for article (PubMed ID: 17986289)

  • 1. Does photodynamic transurethral resection of bladder tumour improve the outcome of initial T1 high-grade bladder cancer? A long-term follow-up of a randomized study.
    Denzinger S; Wieland WF; Otto W; Filbeck T; Knuechel R; Burger M
    BJU Int; 2008 Mar; 101(5):566-9. PubMed ID: 17986289
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinically relevant reduction in risk of recurrence of superficial bladder cancer using 5-aminolevulinic acid-induced fluorescence diagnosis: 8-year results of prospective randomized study.
    Denzinger S; Burger M; Walter B; Knuechel R; Roessler W; Wieland WF; Filbeck T
    Urology; 2007 Apr; 69(4):675-9. PubMed ID: 17445650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fluorescence-guided transurethral resection of bladder tumours reduces bladder tumour recurrence due to less residual tumour tissue in Ta/T1 patients: a randomized two-centre study.
    Hermann GG; Mogensen K; Carlsson S; Marcussen N; Duun S
    BJU Int; 2011 Oct; 108(8 Pt 2):E297-303. PubMed ID: 21414125
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The results of concurrent chemo-radiotherapy for recurrence after treatment with bacillus Calmette-Guérin for non-muscle-invasive bladder cancer: is immediate cystectomy always necessary?
    Wo JY; Shipley WU; Dahl DM; Coen JJ; Heney NM; Kaufman DS; Zietman AL
    BJU Int; 2009 Jul; 104(2):179-83. PubMed ID: 19154448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Should follow-up cystoscopy in bacillus Calmette-Guérin-treated patients continue after five tumour-free years?
    Holmäng S; Ströck V
    Eur Urol; 2012 Mar; 61(3):503-7. PubMed ID: 22119022
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Twelve-year follow up of a randomized prospective trial comparing bacillus Calmette-Guerin and epirubicin as adjuvant therapy in superficial bladder cancer.
    Cheng CW; Chan SF; Chan LW; Chan CK; Ng CF; Cheung HY; Chan SY; Wong WS; Lai FM; To KF; Li ML
    Int J Urol; 2005 May; 12(5):449-55. PubMed ID: 15948743
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999-2001 report from the Japanese Urological Association.
    Kikuchi E; Fujimoto H; Mizutani Y; Okajima E; Koga H; Hinotsu S; Shinohara N; Oya M; Miki T;
    Int J Urol; 2009 Mar; 16(3):279-86. PubMed ID: 19207609
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 5-aminolaevulinic acid-induced fluorescence cystoscopy during transurethral resection reduces the risk of recurrence in stage Ta/T1 bladder cancer.
    Babjuk M; Soukup V; Petrík R; Jirsa M; Dvorácek J
    BJU Int; 2005 Oct; 96(6):798-802. PubMed ID: 16153204
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bladder sparing approach for initial T1G3 bladder cancer: Do multifocality, size of tumor or concomitant carcinoma in situ matter? A long-term analysis of 132 patients.
    Denzinger S; Otto W; Fritsche HM; Roessler W; Wieland WF; Hartmann A; Burger M
    Int J Urol; 2007 Nov; 14(11):995-9; discussion 999. PubMed ID: 17956523
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term follow-up of T1 high-grade bladder cancer after intravesical bacille Calmette-Guérin treatment.
    Kakiashvili DM; van Rhijn BW; Trottier G; Jewett MA; Fleshner NE; Finelli A; Azuero J; Bangma CH; Vajpeyi R; Alkhateeb S; Hanna S; Kostynsky A; Kuk C; Van Der Kwast TH; Zlotta AR
    BJU Int; 2011 Feb; 107(4):540-6. PubMed ID: 21276177
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [BCG versus photodynamic therapy (PDT) for nonmuscle invasive bladder cancer-a multicentre clinical phase III study].
    Jocham D; von Wietersheim J; Pflüger H; Steiner H; Doehn C; Büttner H; Böhle A; Kausch I
    Aktuelle Urol; 2009 Mar; 40(2):91-9. PubMed ID: 19214951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term benefit of 5-aminolevulinic acid fluorescence assisted transurethral resection of superficial bladder cancer: 5-year results of a prospective randomized study.
    Daniltchenko DI; Riedl CR; Sachs MD; Koenig F; Daha KL; Pflueger H; Loening SA; Schnorr D
    J Urol; 2005 Dec; 174(6):2129-33, discussion 2133. PubMed ID: 16280742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial.
    Divrik RT; Yildirim U; Zorlu F; Ozen H
    J Urol; 2006 May; 175(5):1641-4. PubMed ID: 16600720
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined local bladder hyperthermia and intravesical chemotherapy for the treatment of high-grade superficial bladder cancer.
    Gofrit ON; Shapiro A; Pode D; Sidi A; Nativ O; Leib Z; Witjes JA; van der Heijden AG; Naspro R; Colombo R
    Urology; 2004 Mar; 63(3):466-71. PubMed ID: 15028439
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A re-staging transurethral resection predicts early progression of superficial bladder cancer.
    Herr HW; Donat SM
    BJU Int; 2006 Jun; 97(6):1194-8. PubMed ID: 16566813
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Restaging transurethral resection of high risk superficial bladder cancer improves the initial response to bacillus Calmette-Guerin therapy.
    Herr HW
    J Urol; 2005 Dec; 174(6):2134-7. PubMed ID: 16280743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Initial high-grade T1 urothelial cell carcinoma: feasibility and prognostic significance of lamina propria invasion microstaging (T1a/b/c) in BCG-treated and BCG-non-treated patients.
    Orsola A; Trias I; Raventós CX; Español I; Cecchini L; Búcar S; Salinas D; Orsola I
    Eur Urol; 2005 Aug; 48(2):231-8; discussion 238. PubMed ID: 15963635
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Treatment of stage Ta,T1 and Tis bladder tumors using Calmette-Guérin bacillus vaccine].
    Bretheau D; Lechevallier E; Rossi D; Albert P; de Fromont M; Coulange C
    Prog Urol; 1993; 3(4):608-17. PubMed ID: 8401621
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bacillus Calmette-Guérin therapy in stage Ta/T1 bladder cancer: prognostic factors for time to recurrence and progression.
    Andius P; Holmäng S
    BJU Int; 2004 May; 93(7):980-4. PubMed ID: 15142147
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hexaminolevulinate is equal to 5-aminolevulinic acid concerning residual tumor and recurrence rate following photodynamic diagnostic assisted transurethral resection of bladder tumors.
    Burger M; Stief CG; Zaak D; Stenzl A; Wieland WF; Jocham D; Otto W; Denzinger S
    Urology; 2009 Dec; 74(6):1282-6. PubMed ID: 19819538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.